[go: up one dir, main page]

MA50504A - Composés antibactériens - Google Patents

Composés antibactériens

Info

Publication number
MA50504A
MA50504A MA050504A MA50504A MA50504A MA 50504 A MA50504 A MA 50504A MA 050504 A MA050504 A MA 050504A MA 50504 A MA50504 A MA 50504A MA 50504 A MA50504 A MA 50504A
Authority
MA
Morocco
Prior art keywords
antibacterial compounds
antibacterial
compounds
Prior art date
Application number
MA050504A
Other languages
English (en)
Inventor
Cedric Charrier
Nawaz Khan
Paul Meo
Original Assignee
Discuva Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60664899&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA50504(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Discuva Ltd filed Critical Discuva Ltd
Publication of MA50504A publication Critical patent/MA50504A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Warehouses Or Storage Devices (AREA)
MA050504A 2017-11-03 2018-11-02 Composés antibactériens MA50504A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1718285.8A GB201718285D0 (en) 2017-11-03 2017-11-03 Antibacterial Compounds

Publications (1)

Publication Number Publication Date
MA50504A true MA50504A (fr) 2020-09-09

Family

ID=60664899

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050504A MA50504A (fr) 2017-11-03 2018-11-02 Composés antibactériens

Country Status (22)

Country Link
US (2) US11345694B2 (fr)
EP (1) EP3704105B1 (fr)
JP (2) JP7348897B2 (fr)
KR (1) KR102470319B1 (fr)
CN (1) CN111566099B (fr)
AU (1) AU2018361828B2 (fr)
BR (1) BR112020008531A2 (fr)
CA (1) CA3081423A1 (fr)
CL (2) CL2020001147A1 (fr)
CO (1) CO2020005420A2 (fr)
EA (1) EA202091118A1 (fr)
GB (1) GB201718285D0 (fr)
GE (1) GEP20237522B (fr)
IL (1) IL274229B2 (fr)
MA (1) MA50504A (fr)
MX (2) MX2020004562A (fr)
NZ (1) NZ764310A (fr)
PE (2) PE20221006A1 (fr)
SG (1) SG11202003717UA (fr)
UA (1) UA128475C2 (fr)
WO (1) WO2019086890A1 (fr)
ZA (1) ZA202002093B (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201718285D0 (en) * 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds
CA3098428A1 (fr) 2018-04-18 2019-10-24 Constellation Pharmaceuticals, Inc. Modulateurs d'enzymes de modification de methyle, compositions et utilisations de ceux-ci
CA3100977A1 (fr) 2018-05-21 2019-11-28 Constellation Pharmaceuticals, Inc. Modulateurs d'enzymes de modification de methyle, compositions et utilisations de ceux-ci
CN111635372B (zh) * 2020-06-28 2022-05-27 齐鲁工业大学 一种恶唑酮衍生物及其合成方法
MX2023012943A (es) 2021-05-03 2023-11-13 Discuva Ltd Compuesto antibacteriano.
WO2023157628A1 (fr) 2022-02-21 2023-08-24 三井化学株式会社 Élément métallique, corps composite métal-résine et procédé de production d'élément métallique

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA869348B (en) 1985-12-12 1987-10-28 Smithkline Beckman Corp Inhibition of the 5-lipoxygenase pathway
US4780470A (en) * 1986-08-19 1988-10-25 Smithkline Beckman Corporation Inhibition of interleukin-1 by monocytes and/or macrophages
JP2808460B2 (ja) * 1989-11-16 1998-10-08 大正製薬株式会社 イミダゾール誘導体
JPH09124640A (ja) 1995-08-25 1997-05-13 Nippon Soda Co Ltd ピリジルイミダゾール化合物、製法および農園芸用殺菌剤
US6207687B1 (en) 1998-07-31 2001-03-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
CO5271680A1 (es) 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
EP1532118A2 (fr) 2002-07-05 2005-05-25 Axxima Pharmaceuticals Aktiengesellschaft Composes d'imidazole pour le traitement des infections par le virus de l'hepatite c
JP2004196678A (ja) 2002-12-17 2004-07-15 Dainippon Pharmaceut Co Ltd ピラゾール系誘導体
WO2005047266A1 (fr) 2003-11-14 2005-05-26 Lorus Therapeutics Inc. Imidazoles d'aryle et leur utilisation comme agents anticancereux
KR101150077B1 (ko) * 2004-03-05 2012-06-01 다이쇼 세이야꾸 가부시끼가이샤 티아졸 유도체
JP2007277230A (ja) * 2006-03-15 2007-10-25 Tanabe Seiyaku Co Ltd 医薬組成物
US8865732B2 (en) 2008-03-21 2014-10-21 Novartis Ag Heterocyclic compounds and uses thereof
EP2513064B1 (fr) * 2009-12-17 2018-07-04 Katholieke Universiteit Leuven K.U. Leuven R&D Composé, compositions et procédés de lutte contre les biofilms
GB201016261D0 (en) 2010-09-28 2010-11-10 Univ Leuven Kath Compounds for controlling biofilms and process for their production
WO2012135016A2 (fr) 2011-03-25 2012-10-04 North Carolina State University Inhibition de biofilms bactériens et croissance microbienne avec des dérivés d'imidazole
PL2731949T3 (pl) 2011-07-13 2018-10-31 Tiumbio Co., Ltd. 2-pirydylo podstawione imidazole jako inhibitory alk5 i/lub alk4
US8840912B2 (en) 2012-01-09 2014-09-23 North Carolina State University Imidazole derivatives useful for controlling microbial growth
EP3708156A1 (fr) 2014-05-16 2020-09-16 Atriva Therapeutics GmbH Nouvelle stratégie anti-infectieuse contre le virus de la grippe et des coinfections s. aureus
WO2016140884A1 (fr) 2015-03-02 2016-09-09 Rigel Pharmaceuticals, Inc. Inhibiteurs de tgf-β
US20180044316A1 (en) 2015-03-05 2018-02-15 University Of Notre Dame Du Lac Potentiators of beta-lactam antibiotics
CA3030582A1 (fr) 2015-07-22 2017-01-26 The Royal Institution For The Advancement Of Learning/Mcgill University Composes et leurs utilisations dans le traitement de cancers et d'autres etats medicaux
GB201718285D0 (en) * 2017-11-03 2017-12-20 Discuva Ltd Antibacterial Compounds

Also Published As

Publication number Publication date
ZA202002093B (en) 2023-11-29
US20220372027A1 (en) 2022-11-24
CN111566099A (zh) 2020-08-21
CN111566099B (zh) 2023-06-02
US11345694B2 (en) 2022-05-31
NZ764310A (en) 2023-04-28
EP3704105A1 (fr) 2020-09-09
PE20211390A1 (es) 2021-07-27
BR112020008531A2 (pt) 2020-10-20
IL274229A (en) 2020-06-30
JP7348897B2 (ja) 2023-09-21
CL2021002263A1 (es) 2022-04-01
EP3704105B1 (fr) 2024-10-16
IL274229B2 (en) 2023-05-01
EA202091118A1 (ru) 2020-08-06
CA3081423A1 (fr) 2019-05-09
WO2019086890A1 (fr) 2019-05-09
KR102470319B1 (ko) 2022-11-25
AU2018361828B2 (en) 2023-05-18
UA128475C2 (uk) 2024-07-24
CL2020001147A1 (es) 2020-08-14
JP2021501756A (ja) 2021-01-21
AU2018361828A1 (en) 2020-05-28
CO2020005420A2 (es) 2020-07-31
GB201718285D0 (en) 2017-12-20
MX2020004562A (es) 2020-08-13
IL274229B1 (en) 2023-01-01
SG11202003717UA (en) 2020-05-28
US20210163460A1 (en) 2021-06-03
GEP20237522B (en) 2023-08-10
MX2021010246A (es) 2021-09-21
KR20200084875A (ko) 2020-07-13
PE20221006A1 (es) 2022-06-15
JP2022025116A (ja) 2022-02-09

Similar Documents

Publication Publication Date Title
EP3691623A4 (fr) Composés de benzosulfonyle
EP3720430A4 (fr) Composés benzocarbonyle
MA42293A (fr) Composés antibactériens
MA49701A (fr) Composés immunomodulateurs
MA52948A (fr) Composés
EP3578560A4 (fr) Composé de quinazoline
MA51669A (fr) Composés
EP3609871A4 (fr) Composés d'amide aryl cyclopropyl-amino-isoquinolinyl
MA53003A (fr) Composés
EP3853210A4 (fr) Composés antibactériens
LT3468975T (lt) Nauji antibakteriniai junginiai
EP3464336A4 (fr) Composés
PT4039675T (pt) Compostos de fenil-2-hidroxi-acetilamino-2-metil-fenilo
MA50504A (fr) Composés antibactériens
EP4028399C0 (fr) Composés antibactériens
EP3426255A4 (fr) Composés antibactériens et utilisations de ceux-ci
MA44020A (fr) Composés antitumoraux
EP3458041A4 (fr) Compositions antibactériennes
EP3310352A4 (fr) Composés cristallins
MA49621A (fr) Composés bifonctionnels
EP3677246A4 (fr) Composition antifongique antibactérienne
MA49522A (fr) Nouveaux composés de quinoléinone
MA52946A (fr) Composés
MA51221A (fr) Composés de pyrazolopyridinone
EP3713941A4 (fr) Composés de pyrazolopyridinone